In-vitro and in-vivo activity of rifampicin and rifabutin against multi-drug-resistant strains of mycobacterium tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 567s Year: 2002
In vitro susceptibility of mycobacterium bovis against moxifloxacin Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
In vitro activity of moxifloxacin and linezolid against mycobacteriaSource: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients Source: Eur Respir J 2013; 42: 1614-1621 Year: 2013
Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013
In vitro susceptibility of non-tuberculous mycobacterial strains against moxifloxacin Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: diagnostic tools Year: 2012
Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis Source: Eur Respir J 2016; 47: 1229-1234 Year: 2016
Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015
Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601724; DOI: 10.1183/13993003.01724-2016 Year: 2017
Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006
Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
Linezolid in multidrug-resistant tuberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 485s Year: 2004
Amikacin exposure and susceptibility of macrolide-resistant Mycobacterium abscessus Source: ERJ Open Res, 5 (2) 00154-2018; 10.1183/23120541.00154-2018 Year: 2019
Evaluation of a molecular assay for detection of rifampin and isoniazid resistant mycobacterium tuberculosis in strains and clinical samples Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Susceptibility of mycobacterium avium complex and mycobacterium xenopi to rifampin, rifapentine, clarithromycin and moxifloxacin, alone or in combination with ethambutol Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003
Effect of clarithromycin alone and clarithromycin containing regimen for mycobacteriun avium complex pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 558s Year: 2006
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016
The efficacy of a rifabutin-containing regimen for rifabutin-susceptible multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012